首页> 外文OA文献 >Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients
【2h】

Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients

机译:脂质相关抗氧化剂:芳基酯酶和律催碱酶-1在良性前列腺增生治疗 - 诺芬患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Oxidative stress and antioxidants have been implicated in many diseases including prostate cancer and benign prostatic hyperplasia (BPH). Lipid peroxidation contributes to oxidative stress. However, new and emerging antioxidants such as paraoxonase 1 (PON1) and arylesterase (ARE) associated with lipoprotein peroxidation have not been examined in BPH patients. PON1 and ARE, a high-density lipoprotein (HDL) cholesterol-bound enzyme system of antioxidants, protect low-density lipoprotein (LDL) cholesterol and HDL from oxidation by hydrolysis. The study primarily determined paraoxonase (PON1) and ARE activities in BPH treatment-naïve patients.Materials and methods: Sixty newly diagnosed patients (treatment-naïve) alongside 30 apparently healthy controls were recruited. Blood examinations included lipid profile (total cholesterol, triglycerides, LDL, HDL), glutathione peroxidase, PON1, ARE, and prostate specific antigen (PSA).Prostate volume and International Prostate Symptoms Score (IPSS) were determined.Results: PSA was significantly different between patient and control groups (P < 0.0001). Total cholesterol, triglycerides, and LDL were significantly higher in the patient group (P = 0.002, P  0.05), ARE was significantly lower in the patient group (61.31 ± 21.76/49.30 ± 19.82 ng/mL; P = 0.0098). No correlation was established between antioxidants and the lipid profile except for the LDL and PON1 patient group (r = 0.1486, P = 0.0374). Similarly, a weak correlation was also established between PSA and LDL in the patient group (r = –0.275, P = 0.033). PON1/HDL ratio was not significantly different. However, the ARE/HDL ratio was significantly lower in the patient group (P < 0.0001).Conclusion: These results signify the presence of a higher lipoprotein peroxidation activity and lower lipid-associated antioxidant activity in the patient group. The ARE/HDL ratio is a better indicator of the HDL associated antioxidant than the PON1/HDL ratio or the individual antioxidants (PON1 and ARE) as reported by others.
机译:背景:氧化应激和抗氧化剂在许多疾病中涉及,包括前列腺癌和良性前列腺增生(BPH)。脂质过氧化有助于氧化应激。然而,在BPH患者中尚未研究与脂蛋白过氧化吡啶蛋白过氧化相关的亚氧基酶1(PON1)和芳基酯酶(PON1)和芳基酯酶(AS)的新的和新出现的抗氧化剂。 PON1,是一种高密度脂蛋白(HDL)胆固醇结合酶系统的抗氧化剂,通过水解保护低密度脂蛋白(LDL)胆固醇和HDL氧化。该研究主要是确定的律酶(PON1),并且是BPH治疗 - 幼稚患者的活性。材料和方法:招募了六十个新诊断的患者(治疗 - 幼稚),征集30例明显健康的对照。血液检查包括脂质型材(总胆固醇,甘油三酯,LDL,HDL),谷胱甘肽过氧化物酶,PON1,以及前列腺特异性抗原(PSA)。静止体积和国际前列腺症状得分(IPS)。结果:PSA显着不同在患者和对照组之间(P <0.0001)。患者组中总胆固醇,甘油三酯和LDL显着较高(p = 0.002,p 0.05),患者组显着较低(61.31±21.76 / 49.30±19.82ng / ml; p = 0.0098)。除了LDL和PON1患者组之外,抗氧化剂和脂质型材之间没有建立相关性(r = 0.1486,p = 0.0374)。类似地,在患者组中的PSA和LDL之间也建立了弱相关性(R = -0.275,P = 0.033)。 PON1 / HDL比没有显着差异。然而,患者组的均/ HDL比显着较低(P <0.0001)。结论:这些结果在患者组中结合了脂蛋白过氧化活性和降低脂质相关的抗氧化活性。均/ HDL比是与其他人报道的PON1 / HDL比或单个抗氧化剂(PON1)的HDL相关抗氧化剂的更好指示剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号